{SA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Enzymes, Inhibitors, and Substrates, L to O, Lipase, Pancreatic, Lipid Metabolism (Obesity), O, Obesity Research, Roche
{SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Enzymes, Inhibitors, and Substrates, L to O, Lipase, Pancrea
{SNA} Approved Therapeutics/Drug Can
相关文献及参考
[2]. Zhang E, et al. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. Nutrients. 2018 Mar 15;10(3). pii: E353.
[3]. Padwal R, et al. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094.
Lucas, K.H., et al., Orlistat-a novel weight loss therapy. Ann. Pharmacother. 35 , 314-328, (2001)
Merck 14 ,6869
[1]. Zhi J, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995 Nov;35(11):1103-8.
[1]. Zhi J, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995 Nov;35(11):1103-8.
[2]. Zhang E, et al. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. Nutrients. 2018 Mar 15;10(3). pii: E353.
[3]. Padwal R, et al. Lon
安全信息
Personal Protective Equipment
Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter